Singapore permits two change notifications; but the release sequence still matters
A cardiovascular device manufacturer may have several changes ready for Singapore at once: a manufacturing change, revised labelling and a software update. Filing them together can tie their progress to the same application. Filing separately raises a different question: can each change be assessed and implemented without depending on the others?
Singapore’s concurrent change-notification process makes that question more useful. HSA’s September briefing explains that, from 31 July 2026, a device listing may have two active change-notification applications. Only one may amend the device-form fields in SHARE, Singapore’s submission system. [1]
The additional filing capacity can help a company sequence work. Its value depends on how the changes relate to the registered device and to each other.
Two applications do not necessarily mean two independent decisions
HSA’s FAQ distinguishes independent changes from applications with dependencies. Independent changes may generally be processed separately; where one depends on another, processing or approval may depend on that other application. HSA assesses those relationships case by case. [1]
For a development team, the practical issue is whether the second application describes a device that makes sense on its own. Suppose, hypothetically, a catheter manufacturer plans a manufacturing change and a revised instruction that is supported only by evidence from the changed manufacturing process. The two workstreams may have different internal owners, but the evidence connects them. Separating the submissions does not remove that connection.
Conversely, two changes sharing a product name may be technically independent. That is the distinction worth establishing before treating the second filing slot as a shorter route to market.
The device-form restriction creates another constraint. If both proposed applications need to amend those fields, the team needs a different sequence or an appropriate consolidated application. Two available slots do not permit two simultaneous amendments to the same device form. [1]
The limit applies to every listing in the application
GN-21 Revision 7 states that a new application is rejected in full if any included listing already has two active change notifications. Fees already paid are not refunded. [2]
This matters when a manufacturer groups changes across several listings. One busy listing can prevent the combined application from proceeding; the problem is not confined to that listing’s portion of the dossier. HSA also warns that SHARE does not prevent a third submission. A successful electronic submission therefore does not establish that the application is eligible for processing. [1]
Plan the release as well as the filing
Concurrent processing does not change the applicable implementation conditions. GN-21 requires approval for Technical, Review and Administrative changes. Notification-category changes may be implemented after HSA’s acknowledgement, subject to the guidance’s conditions. [2]
Zaliance recommends making the proposed release configurations explicit before choosing the filing structure. If one application finishes first, which version could the company actually supply, and what evidence supports it? If the answer still requires the other change, the commercial schedule should retain that dependency.
The manufacturer and Singapore registrant should work from the same description of the changes, affected listings and proposed sequence. The useful outcome is a filing plan that matches the product the company can release—not simply two applications in progress.
References
[1] HSA. Presentation slides and FAQ, Concurrent Change Notification and Premarket Submission Checklist briefing, 24 September 2026; published 30 September 2026. FAQ, PDF pp. 17–18.
https://file.go.gov.sg/industrybriefingfaq-24-sep-2026.pdf
[2] HSA. GN-21, Guidance on Change Notification for Registered Medical Devices, Revision 7, August 2026. Categories of changes, pp. 10–11; implementation and supply, pp. 34–35; Annex 2, p. 54.
https://go.gov.sg/gn-21-r7-31-07-2026